10 1.05B 1,300 BIOSERVICES Marketed Products 2023 Total Revenue Employees Development Services Drug Substance Drug Product Packaging Molecule-to-Market We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For nearly 25 years, we’ve been at work defending people from things we hope will never happen—so that we’ [...] We do what we do because we see the opportunity to create a better, more secure world. [...] One where preparedness empowers protection from the threats we face. [...] And peace of mind prevails. At Emergent, our mission is to protect and enhance life. [...] Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. [...] Any forward-looking statement speaks only as of the date of publication, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information. [...] There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary language as well as the information identified under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic repor [...] or its subsidiaries in the United States or other countries. EbangaTM is a trademark of Ridgeback Biotherapeutics LP. [...] 07/30/2023 PP-CORP-ALL-00001 These product candidates have not been approved by the U.S. FDA or any other regulatory authority. [...] Status reflects both clinical and nonclinical development under the FDA Animal Efficacy Rule.
- Pages
- 2
- Published in
- United States of America
